Skip to main content

The Children's Vaccine Initiative Continuing Activities (1995) / Chapter Skim
Currently Skimming:

OVERCOMING SCIENTIFIC AND TECHNOLOGICAL BARRIERS
Pages 8-13

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 8...
... For example, it is difficult for a country to justify spending more to immunize its children with a conjugate Hib vaccine than it allocates for the purchase of all seven vaccines called for under the Expanded Programme on Immunization.9 The rationale for buying Hib vaccine is similarly weakened if that cost is two or four times as much as is spent treating all cases of Hib disease in a given year. Improvements in the efficiency of the x Unless otherwise noted, material in this section is based on presentations by John LaMontagne, Philip Russell, and David Briles.
Read the entire page →
From page 9...
... 9 o ~ I ~ I= 3= Cal .
Read the entire page →
From page 10...
... As the number of available vaccines increases and the costs of newer formulations rise, donor agencies are less able to provide vaccine. This creates pressure for developing nations to build domestic manufacturing capacity.
Read the entire page →
From page 11...
... No common-antigen vaccines for pneumococcal disease have yet been tested in humans. Pneumolysin, a cytoplasmic protein, can damage ciliary surfaces of respiratory epithelial cells and cause lesions in the lung that resemble those caused by pneumococcal pneumonia.
Read the entire page →
From page 12...
... The capsular polysaccharides of the group B meningococcus, which causes disease primarily outside of the meningitis belt, are poorly immunogenic in adults and children. One possible explanation is the group B polysaccharides' similarity to static acid moieties on human tissue.
Read the entire page →
From page 13...
... However, recent work by investigators at the Walter Reed Army Institute of Research revealed very little difference in bactericidal titers between vaccines containing class 4 OMP and those without these proteins. More effective adjuvants, such as QS-21 (a plant-derived glucoside)
Read the entire page →

Key Terms

  • capsular polysaccharides
  • conjugate vaccines
  • conjugation process
  • antibody responses
  • clinical trials

  • protein carrier
  • immune response
  • developing world
  • unless otherwise
  • antibody response

  • poorly immunogenic
  • hib vaccine
  • polysaccharide vaccines
  • glycoconjugate vaccines
  • developing nations

  • otherwise noted
  • available vaccines
  • vaccine efficacy
  • conjugate technology
  • carrier protein

  • omp epitopes
  • pertussis component
  • vaccines increases
  • currently poses
  • pneumococcal vaccine

  • walter reed
  • significant barrier
  • bactericidal titers
  • national committee
  • overall disease


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.